Delivery Order SPE2DB22D3009-SPE2DB24FBE59

Award Date 9/4/24
Potential Completion Date 9/5/24
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract valued at $5,239.68 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of XELJANZ XR 11 MG TABLET 30S. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to AmerisourceBergen Drug Corp by DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $3,014.72 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of XELJANZ XR 11 MG TABLET UU 30S. This order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $4,522.05 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide XELJANZ XR 11 MG TABLET UU 30S. This award is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 and a performance period through December 31, 2025 that enables Amerisourcebergen Drug Corp to deliver a comprehensive range of pharmaceutical products and medical...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,411.89 delivery order contract is for the supply of the pharmaceutical product XELJANZ XR 11 MG TABLET. The contract is a firm fixed-price, non-set-aside award with a performance period ending on May 8, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support...
This federal contract award, valued at $11,923.51, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of XELJANZ XR 11 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 6, 2024 and is a firm fixed-price contract. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the pharmaceutical distribution company AmerisourceBergen Corporation, to provide XELJANZ XR 11 MG TABLET medication. The $3,291.07 contract has a performance period through March 27, 2024. This delivery order is issued under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp, which has a potential value of $999,999,999.00 and a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET UU 30S. The contract has a firm fixed price of $17,853.88 and an ultimate completion date of September 10, 2024. This award is a part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET UU 30S. The contract has a ceiling value of $1,669.99 and a performance period through March 11, 2025. The contract is a firm fixed-price type with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $15,793.76, is for the supply of XELJANZ XR 11 MG tablets. The order has a completion date of May 13, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 4,564,235,071 units of the medication XELJANZ XR 11 MG TABLET. The contract has an ultimate completion date of April 11, 2024 and a ceiling value of $8,420.34. This delivery order was issued under an existing indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, which has a...
  • SPE2DB22D3009
    Indefinite Delivery Contract
  • SPE2DB22D3009-SPE2DB24FBE59
    Delivery Order

The Defense Logistics Agency (DLA) awarded a $11,806.87 delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET under contract SPE2DB22D3009. The contract is a firm-fixed-price agreement with a completion date of September 5, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation.

Generated 12/4/24, 9:15 AM